Search results: (10000)
News Current Results of Brigatinib in the Treatment of Lung Cancer
The results of the primary analysis showed a significant extension of PFS in patients with non-small cell lung cancer (NSCLC) treated with brigatinib compared to crizotinib. The recently published secondary analysis confirms these results.
News Impact of Lurasidone on Metabolic Functions Compared to Other Antipsychotics – Results of a Large Meta-Analysis
Antipsychotic therapy is associated with varying degrees of metabolic abnormalities in parameters of weight, lipid metabolism, and glucose metabolism. The presence of metabolic syndrome or isolated disorders of glucose and lipid metabolism further increases the risk of morbidity and mortality in patients with schizophrenia compared to the general population. Lurasidone is an antipsychotic indicated for the acute and maintenance treatment of schizophrenia. The advantage of this drug is its low risk of metabolic side effects, which has been confirmed in a recent large meta-analysis of clinical studies.
News Modern View on Schizophrenia Therapy Through the Lens of Lurasidone
At the psychiatric symposium titled 'Chance for a Better Quality of Life with a Schizophrenia Diagnosis', which took place on October 18, 2021, in Prague, Professor of Psychiatry and Molecular Biology Christoph U. Correll from the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell spoke. His lecture included insights on current approaches to schizophrenia therapy and key information on one of the newest antipsychotics - lurasidone.
News Impact of Physiotherapy and Sports Activities on the Results of Movement Tests in Children with Hemophilia
At the 9th Hemophilia Academy, held online from October 5-7 in Budapest, a lecture by Mgr. Marie Katzerová from University Hospital Brno titled “Physiotherapy, Sports, and Hemophilia” aimed to elucidate the impact of physical activity on the results of movement tests in children with hemophilia.
News Clinical Experiences with Reversing Dabigatran with Idarucizumab
Idarucizumab is an effective specific antidote to dabigatran, which very quickly negates its coagulative effects in cases of severe bleeding conditions or emergency surgical procedures. A Danish retrospective study examined clinical experiences with the use of idarucizumab for blocking dabigatran and related clinical outcomes.
News Real Impact of Lockdown on Asthma Treatment – EAACI Survey Results
Restrictions associated with the COVID-19 pandemic have had a significant impact on the treatment of chronic diseases such as asthma. A study published in the journal Allergy focused on evaluating treatment approaches for adult and pediatric patients with asthma during the coronavirus pandemic lockdowns.
News Efficacy of Brigatinib in Patients with Metastatic NSCLC − Real-World Clinical Data
The journal Lung Cancer published the results of a retrospective analysis of the efficacy of brigatinib in patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who participated in a European early access treatment program.
News Romiplostim in Routine Clinical Use among Patients with ITP in European Countries − Fresh Data Analysis
Data from randomized clinical trials have shown that romiplostim is an effective medication for many patients not only with acute or persistent immune thrombocytopenia (ITP) but also for much more complicated patients with chronic ITP. In April 2021, data on the efficacy and safety of romiplostim from European clinical practice were published.
News Expanded Hemodialysis and Its Impact on Reducing Hospitalization Rates and Medication Usage
The number of patients with end-stage kidney disease is increasing. New approaches and technological advancements in recent decades have contributed to improving hemodialysis treatment. Does the use of so-called expanded hemodialysis lead to better outcomes?
News Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A
With new treatment options for hemophilia A without inhibitors, the question of cost-effectiveness of different treatment approaches arises. The results of a model comparing replacement therapy and emicizumab in terms of cost-effectiveness were presented at a recently held ASH conference.
News Efficacy and Safety of Axitinib in Higher Lines of Renal Carcinoma Treatment in Real Practice
Greek authors published a retrospective study from a single institution and demonstrated that axitinib is a safe and effective treatment option for metastatic renal carcinoma even in ≥ 3rd line treatment.
News Does dabigatran use in women with acute venous thromboembolism reduce the risk of uterine bleeding compared to warfarin?
The use of new oral anticoagulants (NOACs) in patients with deep vein thrombosis is associated with a more favorable safety profile compared to warfarin. However, direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) pose a higher risk of abnormal uterine bleeding. The study presented below compared the risk of this bleeding when using dabigatran (a direct thrombin inhibitor) and warfarin.
News Quality of Life of Hemophiliacs and Ways to Improve It
Determining the quality of life (QoL) also reflects the morbidity associated with the disease, in this case, hemophilia. In the study presented below, the authors focused on determining QoL in relation to socioeconomic and other characteristics.
News Comparison of EHL Products in the Treatment of Hemophilia A – Pharmacoeconomic Analysis
In the work presented below, whose results were recently published, a model combining pharmacokinetic and pharmacodynamic data was developed. With its help, the authors tried to compare the bleeding rates in hemophiliacs treated with various EHL products. At the same time, they focused on the cost-effectiveness of this treatment.
News Individualized Prophylaxis with Achieving Higher Minimum Levels as a Possible Path to Optimal Treatment of Hemophilia A
Prophylactic administration of factor VIII (FVIII) concentrate is the standard of care for individuals with severe hemophilia A. Traditionally, the goal of prophylaxis has been to maintain minimum FVIII levels > 1%. However, it has been shown that this goal may not protect many hemophiliacs from bleeding episodes. So how does prophylaxis that maintains higher FVIII levels stand? These insights were brought by the PROPEL study, whose results were recently published in Blood magazine.
News Biosimilar Bevacizumab in Patients with Non-Small Cell Lung Cancer
Biosimilar drugs are essentially analogous to generics for biological medicines. The patent protection for the original bevacizumab product will expire in the European Union in 2022. Consequently, several companies have already embarked on developing a biosimilar molecule.
News Reduction of Risk of Hospitalizations for Heart Failure in Type 2 Diabetics
The EMPA-REG OUTCOME study already in 2015 highlighted one of the benefits of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, which is the reduction of the risk of hospitalization for heart failure in patients with type 2 diabetes mellitus (T2DM) with high cardiovascular (CV) risk. Compared to placebo, empagliflozin reduced this risk by a relative 35%.
News Is the Quality of Life for Patients with Atrial Fibrillation and Heart Failure Comparable When Treated with Bisoprolol and Digoxin?
The British RATE-AF study, published in December 2020 in the JAMA journal, compared the impact on improving the quality of life in patients with permanent atrial fibrillation (AF) and symptoms of heart failure when administering bisoprolol and low-dose digoxin.
News Efficacy and Safety of Enoxaparin as Bridging Anticoagulant Therapy After Ventricular Assist Device Implantation
The implantation of a ventricular assist device has become an increasingly common method in the treatment of end-stage heart failure in recent years. The implantation of the device necessitates anticoagulant therapy. In the long term, warfarin is most often used according to guidelines, but there are no clear recommendations for early postoperative anticoagulant therapy. The aim of a clinical study published last year was to evaluate the efficacy and safety of enoxaparin as bridging anticoagulant therapy after device implantation within a 3-month postoperative period.
News Administration of Romiplostim in Patients with ITP in Real-World Practice in Central Europe
Data from the PLATON study on the administration of romiplostim in real-world clinical practice in Central and Eastern Europe confirmed very good efficacy in patients with newly diagnosed, persistent, and chronic ITP.
News Biosimilar MB02 as an Alternative to Bevacizumab in Lung Cancer Treatment
The STELLA clinical trial aimed to evaluate the efficacy, safety, and immunogenicity of MB02, a biosimilar to bevacizumab, in patients with advanced non-small cell lung cancer.
News Efficacy and Safety of Gefitinib in Combination with Chemotherapy vs. Chemotherapy Alone in the Treatment of Advanced NSCLC
Non-small cell lung cancer (NSCLC) remains a disease with high mortality. The meta-analysis presented below compared the efficacy and safety of gefitinib in combination with chemotherapy versus chemotherapy alone in the treatment of advanced NSCLC.
News Treatment of Metastatic Colorectal Cancer During the COVID-19 Pandemic
In the conditions of the coronavirus pandemic, it is difficult to maintain good accessibility to ongoing comprehensive oncological care, and thus the quality of life of patients. An international team of researchers focused their survey among oncologists on how the pandemic affects the goals of 3rd line therapy in patients with metastatic colorectal cancer (mCRC) in real clinical practice. The survey results were presented at this year's virtual congress on the treatment of gastrointestinal tumors of the European Society for Clinical Oncology (ESMO).
News Idiopathic Pulmonary Fibrosis: Can This Disease Be Named More Precisely?
Much about idiopathic pulmonary fibrosis (IPF) is still unknown. Some experts would like to reclassify this disease. What classification options are available? What would a focus on the "progressive fibrotic phenotype" in research mean? And what would a change in classification mean for patients?
News Brigatinib in the Therapy of ALK-Positive NSCLC in Patients Refractory to Crizotinib Therapy – Results of the Final Analysis of Clinical Studies
Previously published results of clinical studies have shown that in patients refractory to crizotinib therapy, the administration of brigatinib led to a high rate of therapeutic response (systemic and intracranial) and simultaneously improved median progression-free survival. Additional results presented at this year's ASCO congress included the final outcomes of studies focusing on the administration of brigatinib specifically in patients refractory to crizotinib therapy.